Search Results for "infusers"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for infusers. Results 381 to 390 of 405 total matches.

Tigecycline (Tygacil)

   
The Medical Letter on Drugs and Therapeutics • Sep 12, 2005  (Issue 1217)
of tigecycline is 100 mg IV initially, followed by 50 mg IV every 12 hours. The drug should be infused over 30 ...
Tigecycline (Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Med Lett Drugs Ther. 2005 Sep 12;47(1217):73-4 |  Show IntroductionHide Introduction

Abatacept (Orencia) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
the first infusion. Arthritis Rheum 2002; 46: 1470. 7. JM Kremer et al. Treatment of rheumatoid arthritis ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Med Lett Drugs Ther. 2006 Feb 27;48(1229):17-8 |  Show IntroductionHide Introduction

New Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Nov 12, 2012  (Issue 1403)
infusion reactions, infections, and development of thyroid disorders and immune thrombocytopenic purpura ...
In recent years, several new drugs have been approved by the FDA for use in multiple sclerosis (MS), and many others are in the pipeline. Most recently, teriflunomide (Aubagio – Genzyme) became the second oral drug to be approved by the FDA for treatment of relapsing forms of MS.
Med Lett Drugs Ther. 2012 Nov 12;54(1403):89-91 |  Show IntroductionHide Introduction

Lacosamide for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Jun 29, 2009  (Issue 1315)
taking other drugs that prolong the PR interval. Adverse events with IV infusion over 30 minutes were ...
The FDA has approved lacosamide (Vimpat - UCB Pharma) for oral or intravenous (IV) use as add-on therapy in adults with partial-onset seizures.
Med Lett Drugs Ther. 2009 Jun 29;51(1315):50-2 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
and vomiting are most likely to occur after taking an oral loading dose. Infusion-site reactions were reported ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Romosozumab (Evenity) for Postmenopausal Osteoporosis

   
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019  (Issue 1573)
myeloma, and bone metastases from solid tumors. 9. Cost of one 5 mg/100 mL infusion bottle. 10 ...
The FDA has approved romosozumab-aqqg (Evenity – Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. Romosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor agonists abaloparatide (Tymlos) and...
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-6 |  Show IntroductionHide Introduction

IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting

   
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020  (Issue 1614)
is recommended. Amisulpride should be infused over 1-2 minutes. The drug is subject to photodegradation ...
The FDA has approved IV amisulpride (Barhemsys – Acacia), a selective dopamine-2 and -3 (D2/D3) receptor antagonist, for prevention and treatment of postoperative nausea and vomiting (PONV) in adults. It is the first antiemetic to be approved for rescue treatment of PONV in patients who have symptoms despite receiving antiemetic prophylaxis. Oral formulations of amisulpride are available in Europe for treatment of schizophrenia and acute psychotic episodes.
Med Lett Drugs Ther. 2020 Dec 28;62(1614):205-8 |  Show IntroductionHide Introduction

Choice of Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 1990  (Issue 832)
include thrombophlebitis from intravenous (IV) infusions, pain at intramuscular (IM) injection sites ...
Since the last Medical Letter review of cephalosporin antibiotics (volume 25, page 57, 1983), many new cephalosporins have become available in the USA.
Med Lett Drugs Ther. 1990 Nov 30;32(832):107-10 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
at hourly intervals, if necessary, or continuously at 500 mg/hour by IV infusion. Diazepam − Early ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

Nonopioid Drugs for Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
neuralgia, and intractable neuropathic pain such as poststroke pain and spinal cord injury.40 IV infusions ...
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Med Lett Drugs Ther. 2022 Mar 7;64(1645):33-40 |  Show IntroductionHide Introduction